1.69
Biodexa Pharmaceuticals Plc Adr stock is traded at $1.69, with a volume of 15.93M.
It is up +14.97% in the last 24 hours and down -39.64% over the past month.
Biodexa Pharmaceuticals PLC is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The company combines approved and developed medications with its proprietary and drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients.
See More
Previous Close:
$1.47
Open:
$1.82
24h Volume:
15.93M
Relative Volume:
9.48
Market Cap:
$1.13M
Revenue:
$644.60K
Net Income/Loss:
$-9.87M
P/E Ratio:
-0.00202
EPS:
-837.9618
Net Cash Flow:
$-9.02M
1W Performance:
+37.40%
1M Performance:
-39.64%
6M Performance:
-69.55%
1Y Performance:
-94.17%
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Company Profile
Name
Biodexa Pharmaceuticals Plc Adr
Sector
Industry
Phone
-
Address
-
Compare BDRX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
BDRX
Biodexa Pharmaceuticals Plc Adr
|
1.69 | 1.13M | 644.60K | -9.87M | -9.02M | -837.96 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-08-24 | Initiated | Ladenburg Thalmann | Buy |
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Latest News
Biodexa Pharmaceuticals advances FAP treatment trial By Investing.com - Investing.com South Africa
Biodexa Pharmaceuticals advances FAP treatment trial - Investing.com India
With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter - Barchart.com
Biodexa gets FDA nod for Phase 3 eRapa study in FAP - Investing.com India
BDRXBiodexa Pharmaceuticals plc Latest Stock News & Market Updates - StockTitan
Biodexa selects Precision as CRO for eRapa Phase 3 study in Europe - Investing.com
Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status - Barchart
Biodexa Pharmaceuticals Plc ADR [BDRX] Is Currently 31.94 above its 200 Period Moving Avg: What Does This Mean? - The DBT News
why Teva- Pharmaceutical Industries Ltd. ADR [TEVA] is a Good Choice for Investors After New Price Target of $24.71 - The DBT News
Palantir Technologies Inc [PLTR] Is Currently -0.39 below its 200 Period Moving Avg: What Does This Mean? - The DBT News
Biodexa Pharmaceuticals Plc ADR (BDRX) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
Hesai Group ADR (HSAI) Shares Up Despite Recent Market Volatility - The News Heater
Biodexa Pharmaceuticals Plc ADR (BDRX) vs. Its Peers: A Comparison - The News Heater
Omega Therapeutics Inc (OMGA) Stock: A SWOT Analysis - The News Heater
AES Corp (AES) Shares Down Despite Recent Market Volatility - The News Heater
Altus Power Inc (AMPS) vs. Its Peers: A Comparison - The News Heater
Skechers (SKX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Are Medical Stocks Lagging Argenx (ARGX) This Year? - Yahoo Finance
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the Upgrade - MSN
European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading - MSN
Biodexa Pharmaceuticals Plc ADR (BDRX): A New Perspective - Stocks Register
Result of General Meeting - Yahoo Finance
Gaining Momentum, Biodexa Is Advancing Two Recent Acquisitions Through The Clinic - Barchart
Biodexa Pharmaceuticals regains Nasdaq compliance - Investing.com
Notice of General Meeting - StockTitan
Biodexa Pharmaceuticals Submits SEC Filing with Auditors’ Nod - TipRanks
BDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Biodexa reports promising glioblastoma trial results - Investing.com
Biodexa Pharmaceuticals releases patient updates on PFS, OS from MAGIC-1 study - TipRanks
Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer - StockTitan
Stock Surge: Biodexa Pharmaceuticals Plc ADR (BDRX) Closes at 5.01, Marking a -4.21 Increase/Decrease - The Dwinnex
Biodexa Pharmaceuticals Secures Nasdaq Compliance Extension - TipRanks
Biodexa secures Nasdaq listing extension - Investing.com
Biodexa Pharmaceuticals granted extension to regain compliance with Nasdaq - TipRanks
Biodexa secures Nasdaq listing extension By Investing.com - Investing.com UK
Biodexa Announces Successful Appeal of Nasdaq Delisting - StockTitan
Biodexa provides update on PFS, OS in Phase 1 study of MTX110 in rGBM - TipRanks
Biodexa reports survival rates in glioblastoma study - Investing.com India
Biodexa reports updated Phase 1 data from glioblastoma study (NASDAQ:BDRX) - Seeking Alpha
Biodexa’s MTX110 Shows Promise in Brain Cancer Study - TipRanks
Biodexa reports survival rates in glioblastoma study By Investing.com - Investing.com UK
Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma - StockTitan
Interim results for the six months ended June 30, 2024 - StockTitan
Biodexa Pharmaceuticals Announces ADR Ratio Change - TipRanks
ADR Ratio Change - GlobeNewswire
Biodexa Pharmaceuticals announces ADR ratio change - Investing.com
Biodexa secures full access to cancer research grant - Investing.com
Biodexa Pharmaceuticals Plc ADR (BDRX) produces promising results - US Post News
Receipt of Nasdaq Delisting DeterminationPlans to Appeal - StockTitan
Biodexa Pharmaceuticals sets $5 million offering - Investing.com
Biodexa Pharmaceuticals Plc Adr Stock (BDRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):